Table 1. Demography and other baseline characteristics.
N = number of subjects in specified treatment; n = number of subjects in the specified category; SD = standard deviation; BMI = body mass index; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; RT-PCR = reverse transcription polymerase chain reaction
| Characteristics | Molnupiravir (N = 608), n (%) | Standard of care (N = 610), n (%) |
| Gender | ||
| Male | 408 (67.11) | 425 (69.67) |
| Female | 200 (32.89) | 185 (30.33) |
| Race | ||
| Indian | 608 (100) | 610 (100) |
| Age (years, mean ± SD) | 35.2 ± 10.8 | 34.8 ± 10.8 |
| Height (cm, mean ± SD) | 165.6 ± 9.5 | 165.4 ± 9.4 |
| Weight (kg, mean ± SD) | 65.0 ± 9.1 | 64.2 ± 7.9 |
| BMI (kg/m2, mean ± SD) | 23.5 ± 2.6 | 23.4 ± 2.6 |
| Comorbidities | ||
| Obesity (BMI >30) | 19 (3.12) | 17 (2.78) |
| Diabetes mellitus | 2 (0.32) | 2 (0.32) |
| Hypertension | 3 (0.49) | 7 (1.14) |
| Time since symptom onset | ||
| <3 days | 327 (53.7) | 335 (54.9) |
| 3–5 days | 281 (46.3) | 275 (45.1) |
| SARS-CoV-2 RT-PCR test | ||
| Cycle threshold value (mean ± SD) | 25.9 (3.8) | 25.9 (3.8) |
| Standard of care provided | ||
| Multivitamins, antipyretics and antihistamines | 478 (78.6) | 472 (77.4) |
| Ivermectin | 296 (48.68) | 472 (77.38) |
| Inhalation budesonide | 10 (1.6) | 10 (1.6) |